The drug makers behind two of the most popular weight-loss drugs on the market—Ozempic and Mounjaro—are facing lawsuits claiming that they failed to warn users that the drug can cause paralysis of the stomach.

Lawyers say they believe the evidence supports the claim that Novo Nordisk and Eli Lilly knew about the risks these drugs posed and did not do enough to warn patients.

“Defendants’ inadequate warnings of Ozempic and Mounjaro were acts that amount to willful, wanton and/or reckless conduct,” the lawsuit read. “That said, inadequate warnings in defendants’ drugs Ozempic and Mounjaro were a substantial factor in causing plaintiff’s injuries.”

Paul Pennock, one of the lawyers working on the case from Morgan & Morgan, said he plans on filing more lawsuits in the future as more people come forward.

He said one of his clients is a 44-year-old woman from Louisiana who has taken both drugs, CBS News reported. He said she has been rushed to the emergency room multiple times and has thrown up so violently that she lost some teeth. 

Gastroparesis is a chronic gastrointestinal disorder that causes an individual’s stomach muscles to slow to a crawl and prevents the organ from emptying properly.

TRENDPOST: Last week, we reported on people who claimed to have serious side effects of taking these weight-loss drugs. (See “HORROR STORIES TIED TO WEIGHT-LOSS DRUGS START TO EMERGE” 1 Aug 2023.)

We have reported extensively on the recent emergence of weight-loss super drugs that help keep hunger suppressed in patients. These drugs are seen by promoters as a potential quick fix to obesity and a potential boon to the pharmaceutical industry that is in a Fat Race. (See “OPERATION WARP SPEED: OBESITY ADDITION” 27 Jun 2023, “JENNY CRAIG TO CLOSE ITS DOORS, CAN’T COMPETE WITH NEW WEIGHT-LOSS DRUGS” 9 May 2023, and “WEIGHT-LOSS SURGERY FOR CHILDREN IN U.S. JUMPS…WHO CARES ABOUT DIET?” 25 Apr 2023.)

Ozempic and Mounjaro were originally prescribed for diabetics. They are considered GLP-1 agonists that seem to help people lose weight. Food is metabolized slower, so individuals feel fuller, longer.

NBC News reported that “gastroparesis” is not named in the prescribing information for these two drugs, but both labels warn of “delays” in gastric emptying.

Chanapa Tantibanchachai, a spokesperson for the Food and Drug Administration, declined to comment on the NBC report but said it is unclear if the GLP-1 medications contribute to the occurrence of gastroparesis.

Novo Nordisk told NBC that the company was not aware of the lawsuits as of Wednesday morning but noted that gastroparesis is a known risk for people with diabetes.

Jaclyn Bjorklund, the patient named in the initial lawsuit, was diagnosed with Type 2 diabetes in 2017, according to the report. She has not been officially diagnosed with gastroparesis, but her symptoms are “indicative” of the problem, her lawyer said.

One of the reasons The Trends Journal covers these issues is because it represents a societal disease. The U.S. is a country hooked on fast food and fast medications, and the human body was not designed for such dramatic fluctuations. The problem is that there’s a great deal of money to be made by drug dealers and fast-food restaurants, and their advertising is the lifeblood for news outlets.